Characterization of sequence-dependent synergy between ZD1839 (‘Iressa’) and oxaliplatin

This publication has 25 references indexed in Scilit:

• Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
  British Journal of Cancer, 2002
• Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
  British Journal of Cancer, 2002
• Anticancer therapy targeting the erbB family of receptor tyrosine kinases
  Seminars in Oncology, 2001
• Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
  British Journal of Cancer, 2001
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000
• ZD1839 (???Iressa???)*,??? as an Anticancer Agent
  Drugs, 2000
• The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
  Pharmacology & Therapeutics, 1999
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
  Journal of Clinical Oncology, 1998
• Epidermal Growth Factor Receptor Family and Chemosensitization
  JNCI Journal of the National Cancer Institute, 1997
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
  Annals of Oncology, 1996